Table 1.
Characteristics of study participants
| A. HNRP cohort | ||||
| Clinical variable | All samples (n=28) | NCI (n=14) | Normal (n=14) | p value* |
| Gender (% males) | 96 % | 100 % | 0.93 | 1 |
| Ethnicity (% Caucasian) | 80 % | 79 % | 64 % | 0.68 |
| Age | 46.5 (37.75–49.25) | 47 (39–49) | 45.5 (35.5–52) | 0.65 |
| ART naive | 46 % | 50 % | 43 % | 1 |
| CSF HIV RNA (log10 copies/mL) | 2.58 (1.68–341) | 2.25 (1.68–3.71) | 2.58 (1.68–3.26) | 0.94 |
| CSF VL >50 HIV RNA copies/mL (%) | 62 % | 57 % | 67 % | 0.70 |
| CD4+ T cell counts (cells/µL) | 386 (155.5–347) | 391 (356.25–481.25) | 369 (347–500) | 0.77 |
| CD4 percentage (%) | 22 (17.2–25.7) | 20 (17.15–23.98) | 23.1 (21.7–28.3) | 0.3 |
| CD8+ T cell counts (cells/µL) | 1006 (767.5–1260.5) | 1112 (908.5–1470.5) | 945 (655–1126) | 0.08 |
| CD8 percentage (%) | 54.6 (47.2–59.15) | 54.05 (50.35–58.68) | 54.6 (40.1–59,6) | 0.65 |
| CD4/CD8 ratio | 0.41 (0.28–0.49) | 0.4 (0.28–0.45) | 0.42 (0.36–0.76) | 0.34 |
| CD4 nadir (cells/µL) | 244 (124.5-330.75) | 240 (99–303.25) | 252 (145.5-341.75) | 0.67 |
| Global deficit score | 0.49 (0.17–0.68) | 0.72 (0.58–1.26) | 0.17 (0.11–0.22) | 7.32E−06 |
| B. ART interruption cohort | ||||
| Clinical variable | All samples (n=5) | |||
| Gender (% males) | 100 % | |||
| Ethnicity (% Caucasian) | 80 % | |||
| Age | 43 (34–51) | |||
| CSF VL <50 HIV RNA copies/mL (%) | 100 % | |||
| CD4+ T cell counts (cells/µL) | 863.5 (700.25–1040) | |||
| CD4 percentage (%) | 35 (33.75–37.25) | |||
| CD8+ T cell counts (cells/µL) | 881.5 (810–958.25) | |||
| CD8 percentage (%) | 39.5 (34.75–43.25) | |||
| CD4/CD8 ratio | 0.94 (0.80–1.18) | |||
| CD4 nadir (cells/µL) | 281 (215–394.75) |
Median and interquantile range values are shown for the both cohort (A, B) and by groups defined by neurocognitive performance (NCI vs NCN) in the HNRP cohort (A)
*
Represent the p value of a double-tailed Mann-Whitney or a Fisher test